A sensitive HPLC method for the assessment of metabolic conversion of estrogens
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This paper describes a sensitive high-performance liquid chromatography (HPLC) method for measuring the metabolic conversion of estrogens.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Disorders of estrogen-responsive tissues are frequently associated with aberrations in steroid metabolism due to altered expression of synthesizing and metabolizing enzymes. For instance, overexposure to unopposed 17beta-estradiol has been associated with the pathogenesis of endometrial proliferative disorders, such as endometriosis. Investigations into the metabolic conversion in tissues and cells have been rather limited. This is mostly due to fact that such studies have to make use of radioactive steroid hormones and expensive equipment to obtain sufficient sensitivity. We adapted a sensitive non-radioactive HPLC method to study estrogen metabolism in more detail. This HPLC method is based on the solid phase extraction of estrogens and the derivatization of the steroids with 2-(4-carboxy-phenyl)-5,6-dimethylbenzimidazole. The technique is sensitive, robust and is useful for the detection of aromatase, 17beta-HSD types 1 and 2 and sulfatase activities in lysates of placenta and endometrium.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (22)
- Endometriosis: Role of Ovarian Steroids in Initiation, Maintenance, and Suppression via openalex
- W1967605597 via openalex
- W1968016317 via openalex
- W1980913795 via openalex
- W1984291010 via openalex
- W1991354897 via openalex
- W2001810436 via openalex
- W2007017846 via openalex
- W2013903932 via openalex
- W2024004800 via openalex
- W2051091318 via openalex
- W2053311013 via openalex
- W2066518128 via openalex
- W2067600971 via openalex
- W2079593503 via openalex
- W2084051464 via openalex
- W2122860305 via openalex
- W2519503820 via openalex
- W2625764402 via openalex
- W4300443551 via openalex
- W1525342509 via openalex
- W6844441291 via openalex
Cited by (6)
- An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis 2022
- Inhibition of Type 1 17β-Hydroxysteroid Dehydrogenase Impairs the Synthesis of 17β-Estradiol in Endometriosis Lesions 2013
- Novel Hydroxysteroid (17β) Dehydrogenase 1 Inhibitors Reverse Estrogen-Induced Endometrial Hyperplasia in Transgenic Mice 2010
- Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis 2008
- Increased Production of 17β-Estradiol in Endometriosis Lesions Is the Result of Impaired Metabolism 2008
- Estrogen metabolizing enzymes in endometrium and endometriosis 2007
Source provenance
- europepmc
- last seen: 2026-08-02T06:10:09.037253+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:15:00.519696+00:00
- unpaywall
- last seen: 2026-08-02T06:40:33.490260+00:00
License: CC0
· commercial use OK